• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 6th February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.

_DSC0113
Claud Theakston
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Fishing on the lake at sunset. Fishing background.

How can fair pricing systems for medicines that balance both access and innovation be designed? This was the question posed by the inaugural OHE Policy Innovation Prize. This Insight looks at how the winning proposal, Professor Aidan Hollis’ Optional Delinked Rewards System (ODRS), responds to this challenge, and discusses potential benefits, as well as what challenges it might face.

At the beginning of his acceptance speech, Professor Hollis invited us to consider innovative drug pricing and reimbursement with a fishing analogy. There are multiple strategies for catching fish, for example, casting with bait, fly fishing, bottom fishing, using nets/traps, etc., and different fish require different strategies and tackle.

Similarly with drug innovation, the same strategy doesn’t work for all medicines. By using new and different strategies, in parallel with existing ones, we should support innovation, increase access, and ‘catch’ more innovative drugs.

At present, innovative drugs are usually reimbursed at an initially high price, necessary to recoup the costs involved in research and development. However, this often presents an issue to payers with budget constraints. This system rewards innovation, but does not achieve access.

How can we achieve both? The Optional Delinked Rewards System proposes a 2-part tariff, with a separate ‘reward’ payment for innovation and health gains afforded, on top of the initial payment for manufacturing and distribution of the product. Being optional, this alternative, flexible, instrument would delink prices, allowing health systems and payers to initially purchase new drugs at prices close to those of generics, facilitating greater patient access and placing less strain on budgets.

Additional reward payments would then be made over the course of a 10-year period, in a transparent, mechanical, and non-negotiable process. Rewards would be performance-based – directly linked to the incremental health gains afforded by the drug, and could be flexible to different contexts.

So how would this novel reward system make a difference?

Potential benefits include:

  • Firms would no longer face drawn-out negotiations with opportunistic insurers, therefore expediting patient access.
  • Increased usage of new medical innovations because of low initial price per unit.
  • Better pricing strategies for multi-indication products; rewards, rather than prices, would be linked to value.
  • Solving patent protection problems and rushed clinical trials.
  • Promoting innovation on indications currently avoided due to lengthy clinical trial requirements.
  • Internationally, the possibility of solving the European pricing problem, as contributions to reward payments can be adjusted for different affordability levels for individual countries.
  • Increased innovation in areas where it is currently lacking, such as the production of drugs for diseases that primarily affect poorer populations with a lower ability to pay.

Despite numerous benefits – which are simultaneously ambitious, practical, and impactful – limitations and challenges remain.

Questions include:

  • How would drugs on this optional 2-part tariff compete with single-price products?
  • What would optionality look like, on an individual drug basis, or for an entire therapeutic class?
  • How would differential reward systems work for payers with a fixed budget?
  • If the rewards are linked to value, how would the budget impact on payers differ from Value-Based Pricing?
  • Might retroactive adjustment be needed?
  • How would this be coordinated on a complex international scale?

While questions like these remain, the ODRS proposal holds real potential for the future, so long as it is clear what it is being applied to achieve. Which drugs are we trying to ‘catch’, and which will elude us?

Beyond this, it is worth considering the success of the Policy Innovation Prize in similar terms – what new methods, strategies, and proposals can we develop by generating more innovative research on this important topic?

Although there is no silver bullet to such a fundamental and challenging topic, there have been innovative proposals and the success of the policy prize lies in having more people address this topic from new angles, increasing the corpus of knowledge and quality of debate.

  • Innovation Policy Prize
  • Economics of Innovation
  • 60th Anniversary

Related Insights

Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1
  • Insight
  • December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!